We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.76 | -0.23% | 774.99 | 802 | 09:24:57 |
From May 2019 to May 2024
By Andrew Morse
ZURICH--Novartis AG on Thursday reported a huge rise in first-quarter earnings as the completion of a major transaction delivered exceptional gains.
Basel-based Novartis said net profit attributable to shareholders leapt to $13 billion from $2.94 billion a year earlier as the company closed deals with GlaxoSmithKline and Eli Lilly and Co.
The company said the sales resulted in an exceptional operating income gain of $12.8 billion and a net income gain of $10.8 billion.
Net income from continuing businesses, which reflects the company's actual businesses, fell to $2.31 billion from $2.45 billion a year earlier.
The pharmaceutical giant reported sales dropped 7% to $11.94 billion from $12.77 billion a year earlier based on operations the company still owned. Analysts had forecast $12.61 billion.
The performance comes shortly after Novartis completed a series of transactions valued at more than $25 billion that refocused the drug group on three core areas: pharmaceuticals, generics and eye care. The sweeping overhaul, which included the purchase of GlaxoSmithKline's oncology unit, has transformed Novartis into a cancer powerhouse with roughly a fifth of its revenue expected to come from cancer drugs.
The overhaul has also opened up new opportunities for Novartis to cut costs by consolidating support functions that had previously been spread throughout the company.
Write to Andrew Morse at andrew.morse@wsj.com
Access Investor Kit for Novartis AG
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=CH0012005267
Access Investor Kit for GlaxoSmithKline Plc
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=GB0009252882
Access Investor Kit for GlaxoSmithKline Plc
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US37733W1053
Access Investor Kit for Eli Lilly & Co.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US5324571083
Access Investor Kit for Novartis AG
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US66987V1098
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
